Clinical studies are a type of medical research designed to better understand a disease. They can also explore different ways to treat a health condition, including developing new medicines that aren’t currently available.
Researchers test a specific intervention, such as a new medicine, according to a detailed research plan. Health regulators, like the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA), approve these plans and oversee the development of new medicines.
New medicines being tested in clinical trials are considered “investigational” only. During a series of trials, researchers monitor the safety and effectiveness of the medicine and compare results among the participants.
Researchers monitor individuals in their usual environment, without changing their activities, and track specific health information. For example, researchers want to learn more about the impact of sleep on overall health. Their study might look at individuals who sleep more than 6 hours a night compared to those who sleep less than 6 hours a night. The researchers would monitor any changes in overall health between these two groups.
During observational studies, researchers do not give investigational treatments to participants.
There are typically four phases of clinical trials during the drug development process. These trials evaluate the safety and effectiveness of a potential medicine. Each phase can take months, sometimes years, and must be successfully completed before moving to the next phase.
After all the phases are complete, even more time is spent compiling and reviewing the data. Most companies start with thousands of potential medicines, but very few make it to Phase 1 and even fewer get approved.
Researchers test a medicine in a small group of “normal, healthy human volunteers,” meaning they do not have the condition the medicine is designed to treat. These tests evaluate safety, potential side effects, and the most appropriate amount of medicine to take.
The medicine is given to a larger group of individuals who have the condition the medicine is intended to treat. During this phase, researchers try to get “proof” that the medicine could work, also known as “proof of concept.” This phase further evaluates safety, the most appropriate amount of medicine to take, and early data about how well the medicine may work.
After the treatment has been approved, researchers may continue to track it to gather more information about the medicine’s safety, benefits, and most appropriate use.
(FDA) or the European Medicines Agency (EMA), to share data and information from its trials. These health authorities will decide if a medicine can be approved for use, based on the results of the trials. Approval of a medicine in one country does not mean that it is approved for use in another.
Not all medicines are approved for use, or even make it to Phase 3. Clinical trials are basically an experiment, and events or findings along the way can impact the development process. For example, not recruiting participants in time may delay the overall timing of the trial.
Other challenges that could slow or stop a trial completely include: unexpected negative safety findings, results that show a medicine doesn’t really work, or inconsistent quality manufacturing of the medicine.
Although the drug development process can be unpredictable, it helps both science and medicine advance.
Each clinical study outlines specific requirements, called the “eligibility criteria,” to determine who is able to participate.
Eligibility criteria can include factors such as age, gender, type and stage of a disease, and medical history. Factors that allow an individual to participate are called inclusion criteria; factors that disqualify an individual from participating are called exclusion criteria.
A trial doctor, known as an investigator, determines who is eligible to participate in the study.
The reasons individuals may decide to join a trial vary greatly, as this is a personal choice that must be carefully considered prior to participation. For example, they might join to gain access to a specialist or to a new medicine. They might also join to actively participate in medical and scientific research. Other considerations include frequency of appointments or potential travel required.
It’s important to note that investigational treatment involves some risk. Researchers closely monitor participants for safety, but not all of the effects are known.
The first step when considering enrollment in a clinical trial is a conversation between the potential participant and his or her doctor to discuss the appropriateness of the trial and address any questions. If the trial is appropriate, screening sites can then determine whether the individual is eligible.
Each of the below studies evaluates the use of setmelanotide in individuals with rare genetic disorders of obesity.
Setmelanotide for the treatment of LEPR deficiency obesity
IN INDIVIDUALS WITH
IN INDIVIDUALS WITH
⋅ LEPR deficiency obesity
(early onset)
STATUS
Active/not recruiting
Setmelanotide (RM-493), melanocortin-4 receptor (MC4R) agonist, in Bardet-Biedl syndrome (BBS) and Alström syndrome (AS) patients with moderate to severe obesity
IN INDIVIDUALS WITH
IN INDIVIDUALS WITH
⋅ Bardet-Biedl syndrome with moderate to severe obesity
⋅ Alström syndrome with moderate to severe obesity
STATUS
Active/not recruiting
Setmelanotide for the treatment of early-onset POMC deficiency obesity
IN INDIVIDUALS WITH
IN INDIVIDUALS WITH
⋅ POMC deficiency obesity (early onset)
STATUS
Active/not recruiting
Long-term extension trial of setmelanotide
IN INDIVIDUALS WITH
IN INDIVIDUALS WITH
⋅ rare genetic disorders of obesity who previously participated in an interventional trial for setmelanotide
STATUS
Active/recruiting
Setmelanotide Phase 2 treatment trial in patients with rare genetic disorders of obesity
IN INDIVIDUALS WITH
IN INDIVIDUALS WITH
⋅ Heterozygous POMC, PCSK1, or LEPR gene variants
⋅ POMC deficiency obesity
⋅ LEPR deficiency obesity
⋅ Smith-Magenis syndrome
⋅ SH2B1 deficiency obesity (including 16p11.2 deletions)
⋅ Leptin deficiency obesity with
loss of response to leptin
replacement therapy (i.e.
metreleptin)
⋅ SRC1 deficiency obesity
⋅ MC4R deficiency obesity
STATUS
Active/recruiting
Each of the below studies aims to better understand rare genetic disorders of obesity without a therapeutic intervention.
Genetic testing and phenotypic characterization of severely obese pediatric and adult volunteers
IN INDIVIDUALS WITH
IN INDIVIDUALS WITH
⋅ Severe obesity (both children and adults)
STUDY OBJECTIVE
Identify individuals with a rare genetic cause of obesity via screening
STATUS
Active/not recruiting
An observational, prospective natural history study of early-onset extreme obesity due to bi-allelic loss-of-function mutations in the POMC, PCSK1 or LEPR genes (NHS)
IN INDIVIDUALS WITH
Bi-allelic loss-of-function genetic variation resulting in:
IN INDIVIDUALS WITH
Bi-allelic loss-of-function genetic variation resulting in:
⋅ POMC deficiency obesity
⋅ PCSK1 deficiency obesity
⋅ LEPR deficiency obesity
STUDY OBJECTIVE
Collect information from people with early-onset extreme obesity due to specific genetic variations
STATUS
Active/recruiting
The TEMPO (tracing the effect of the MC4 pathway in obesity) registry
IN INDIVIDUALS WITH
IN INDIVIDUALS WITH
⋅ MC4R-pathway genetic obesity
STUDY OBJECTIVE
Develop a registry of individuals to try to better understand the impact of the MC4R pathway in obesity
STATUS
Closed
LEPR, leptin receptor; MC4R, melanocortin-4 receptor; PCSK1, proprotein convertase subtilisin/kexin type 1; POMC, proopiomelanocortin
Before an individual agrees to participate in a trial, he or she must complete an informed consent document. This means that researchers have provided the participant with key facts about the trial, including required procedures and frequency, potential effects of the medicine, and contact information. Signing this document shows that the individual understands the study and agrees to participate.
Every clinical trial must follow a detailed plan, called a “protocol”. The protocol outlines the study rationale, objectives, and design, and is strictly monitored for adherence to scientific and ethical standards. It includes information about participation criteria, study length, treatment dosage, and any required procedures.
A placebo is a substance that has no effect. It usually comes in the same form as the medicine that is being tested, but does not contain any medicine. Placebos can be used in studies to examine the effectiveness of a medicine by comparing results between individuals who received the medicine and those who received the placebo.
Sometimes also called “compassionate use” or “early access,” expanded access is a way to gain access to an investigational medical treatment when no alternative therapy options are available. This approach typically applies only to individuals with an immediately life-threatening condition or serious disease or condition, and when enrollment in a clinical trial is not possible. With expanded access, no comparable or satisfactory treatment is available, the potential benefit must outweigh the treatment risk, and taking the investigational treatment must not interfere with the development or approval of the medicine.
It’s important to know that expanded access is not offered for all medicines. Companies often include specific policy details on their websites. Rhythm’s expanded access policy is available here.
Although every trial is different, participation is usually free. The sponsor of the trial usually pays for doctor visits and medicine; travel expenses are also usually covered. You should always check with your doctor and the trial sponsor to understand costs for which you could be responsible.
Yes. Participating in the research study is optional. It is on a volunteer basis and individuals can choose to withdraw their participation at any time.
